February 19, 2026, New York City, New York, USA: Moderna just announced that the Food and Drug Administration will review its new flu vaccine that uses mRNA technology, a flip from the shocking refusal the FDA announced last week. Moderna said it tweaked its application after meetings with regulators, specifically regarding its trials for older adults. The FDA will issue its decision on the new flu shot in August, ahead of this year’s flu season. Apple Iphone screengrab of the Moderna company website banner page. (Credit Image: © Billy Tompkins/ZUMA Press Wire) EDITORIAL USAGE ONLY! Not for
GLIX-115-3DRWCA9
Kizárólag sajtó felhasználásra.
Magyarország
NEM engedélyezett felhasználási módok:
personalUse advertisingCommercialUse commercialElectronicUse consumerGoodsUse directMailBrochuresUse indoorDisplayUse internalBusinessUseKollekció
GLIX Prime
Fotós / Szerző
ZUMA Press, ZUMA Press, Inc.
Készült
Leírás
February 19, 2026, New York City, New York, USA: Moderna just announced that the Food and Drug Administration will review its new flu vaccine that uses mRNA technology, a flip from the shocking refusal the FDA announced last week. Moderna said it tweaked its application after meetings with regulators, specifically regarding its trials for older adults. The FDA will issue its decision on the new flu shot in August, ahead of this year’s flu season. Apple Iphone screengrab of the Moderna company website banner page. (Credit Image: © Billy Tompkins/ZUMA Press Wire) EDITORIAL USAGE ONLY! Not for